Invitae has developed tools to help health care workers order genetic testing via telemedicine for patients with cancer and newly pregnant women.
Invitae’s clinical chatbot, Gia, provides telemedicine genetic testing framework that helps identify patients who need germline genetic testing.
Clinicians are turning to telemedicine for patients who face disruptions to clinic visits, such as women who are newly pregnant or patients with cancer. Adapting to remote care requires tools that make it easier to replace tasks that were previously handled in-person, such as patient education or information gathering. Invitae has added new telehealth workflows to Gia for clinicians.
“Genetic testing plays an important role in clinical care. We’ve expanded Gia’s capabilities to give clinicians a virtual go-between that can handle many elements of patient education, identification and information gathering involved in genetic testing,” Robert Nussbaum, chief medical officer of Invitae, said in a statement. “Coupled with our ability to ship test kits to and from a patient’s home that use saliva and do not require phlebotomy, we can help clinicians continue to provide care from afar.”
Gia stands for “genetic information assistant” and streamlines communication between patients and clinicians. It automates pretest education and genetic testing. Gia is HIPAA-compliant and SOC-2 certified. It also has a 92% satisfaction rate.
Gia includes patient identification, pre-test education, post-test support and automated documentation that is available 24/7. Gia can also help identify patients that may be at increased risk for breast, endometrial, ovarian, pancreatic, colon and prostate cancer and may benefit from genetic testing as a screening tool.
